Immunotherapy, gene and cell therapy, target drug delivery with nanoparticles, synthetic lethality or drug repurposing are examples of research on advanced therapies that can be applied to a number of oncological, cardiovascular or neurological diseases among others. Research is this programme will lead to new treatments and therapeutic strategies to improve patients’ lives.
Technological and bioinformatics advances in the field of genomics led to a strong impact not only on the diagnosis of rare genetic diseases but also on determining risk factors, prognosis and treatment of a growing number of highly prevalent pathologies. In this programme we face the era of personalized precision medicine and address the challenge of diagnosing genetic disorders sooner and better.
Research on disease biomarkers are essential in high complexity medical care as it allows to adjust the diagnosis and predict the prognosis and drug response. Biomarkers are also essential for the proper follow-up of clinical trials with new drugs. The research done in this program will help define what is the best journey for our patients, from diagnosis and clinical follow-up to treatment.
We are an Institute with healthcare professionals linked to all medical specialties and nursing. The translational research of this program aims to respond to the clinical challenges of patients in the form of healthcare improvements. This is evident in improvements in diagnosis, medical or surgical procedures or care circuitsalways focused to the benefit of the patients.
The outbreak of the SARS-CoV-2 virus and the consequent pandemic has driven many research projects on COVID-19, including the effects on pregnancy and childbirth, the genetic or individual factors that determine its severity, the physiological mechanisms of infection and immune response, or clinical trials with new drugs. This program adds knowledge for a common goal: understand to fight the disease.